Wall Street analysts forecast that Champions Oncology Inc (NASDAQ:CSBR) will post ($0.02) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Champions Oncology’s earnings. Champions Oncology reported earnings of $0.03 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 166.7%. The business is expected to announce its next earnings results on Monday, December 16th.
On average, analysts expect that Champions Oncology will report full-year earnings of $0.01 per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of $0.20 per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last announced its earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.09). Champions Oncology had a negative return on equity of 48.07% and a negative net margin of 3.61%. The business had revenue of $6.74 million for the quarter, compared to analysts’ expectations of $7.50 million.
Several equities analysts have recently commented on CSBR shares. Janney Montgomery Scott lowered Champions Oncology from a “buy” rating to a “neutral” rating in a report on Wednesday, July 24th. Zacks Investment Research raised Champions Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, September 24th. ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, Roth Capital started coverage on Champions Oncology in a report on Friday, September 20th. They set a “buy” rating and a $9.25 target price for the company. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Champions Oncology has an average rating of “Buy” and a consensus price target of $13.13.
Shares of NASDAQ CSBR traded down $0.04 during midday trading on Tuesday, reaching $5.26. 27,400 shares of the company’s stock were exchanged, compared to its average volume of 41,816. The stock has a market capitalization of $61.00 million, a PE ratio of 526.00 and a beta of 1.15. The business’s fifty day moving average price is $5.72 and its two-hundred day moving average price is $7.15. Champions Oncology has a 52-week low of $5.01 and a 52-week high of $14.04. The company has a debt-to-equity ratio of 2.06, a quick ratio of 0.80 and a current ratio of 0.80.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP boosted its position in shares of Champions Oncology by 51.0% during the second quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock worth $192,000 after buying an additional 8,279 shares during the period. Marshall Wace LLP acquired a new position in shares of Champions Oncology during the first quarter worth approximately $99,000. Alambic Investment Management L.P. boosted its position in shares of Champions Oncology by 27.0% during the second quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock worth $538,000 after buying an additional 14,614 shares during the period. BlackRock Inc. boosted its position in shares of Champions Oncology by 12.0% during the second quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after buying an additional 14,733 shares during the period. Finally, Wedge Capital Management L L P NC acquired a new position in shares of Champions Oncology during the second quarter worth approximately $277,000. Institutional investors and hedge funds own 51.62% of the company’s stock.
Champions Oncology Company Profile
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Further Reading: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.